Global skin tightening market is expected to reach USD 2,222.27 million by 2026 from USD 1,283.85 million in 2018, at a CAGR of 7.2% in the forecast period of 2019 to 2026. The years considered for the study are as mentioned below. Access Full Report at https://databridgemarketresearch.com/reports/global-skin-tightening-market Global skin tightening market is a highly concentrated market which includes key players and local players. The market has witnessed various strategic developments owing to favourable market scenario. The market has a prominent growth in upcoming years due to increase in increasing demand for the non-invasive skin tightening techniques and rising demand of skin tightening treatment. Emerging markets an offer and growth opportunity which is also posing as an opportunity for the market. The market has witness developments in terms of merger and acquisitions or product launches to enhance the product portfolio to meet the rising demand of innovative technology. For instance, In In February, 2017, Venus Concept Ltd. acquired NeoGraft Solutions, Inc. (U.S.). This acquisition helped in broadening company’s (Venus Concept Ltd) current customer base and product portfolio. By this acquisition company strengthen its product portfolio and operation excellence. Merz Pharma dominated the global skin tightening market and accounts for the highest market share in 2018 which is followed by Bausch Health Companies Inc. and Hologic, Inc. The other key players in the market are BTL, ALLERGAN, BISON MEDICAL, Pollogen, BRERA MEDICAL TECHNOLOGIES S.R.L., Cutera, Opatra Ltd, Venus Concept, Alma Lasers, Beijing Winkonlaser Technology Limited, DEKA M.E.L.A. srl, Fotona, ThermiGen, LLC, EINSMED Co.,Ltd and others. Merz Pharma Merz Pharma is headquartered in Frankfurt, Germany and was founded in 1908. The company focuses towards the development of medical aesthetics and neurotoxin therapy areas. The company has three operating business by different product category as aesthetics, neurotoxins, regional brands’ The aestheticsis is market focused category. The company’s total employees are 3,151 as of December 2018. The company’s revenue is USD 1,222.11 million in 2018. The company has global presence in North America, Asia-Pacific, Latin America, Europe, Middle East and Africa. The company has various subsidiaries such as Merz North America, Inc. (U.S.), Anteis S.A. (Switzerland), Merz Pharma France (France), Merz Pharma GmbH (Germany), Merz Pharmaceuticals, LLC (U.S.) and others. Bausch Health: Bausch Health headquartered in Laval, Canada was founded in 1983. The company focuses on the manufacture and sales a wide range of branded, generic pharmaceutical and OTC products as well as medical devices. The company has three operating divisions’ bausch+lomb/international, salix, ortho dermatologies, diversified products. The ortho dermatologies is market focused segment. The dermatologist segment revenue is USD 625 million in 2018 and USD 725 million in 2017. The revenue of ortho dermatologist segment has decreased by 14% compared than previous year. The decrease is due to increasing competition in the market. The company total employees 21,100 as of December 2018. The company has global presence in North America, Asia-Pacific, Latin America, Europe, Middle East and Africa The company’s revenue is USD 8,380.00 million in 2018. The company has various subsidiaries such as Bausch & Lomb Inc (U.S.), Solta Medical International Inc (U.S.), Salix Pharmaceuticals (U.S.), OraPharma, Inc (U.S.), Valeant Canada Ltd (Canada), Coria Laboratories, Ltd (U.S.). Hologic, Inc. The company is headquartered in Massachusetts, U.S. was founded in 1986. The company is engaged in developing, manufacturing and supplying of premium diagnostics products, medical imaging systems, surgical products and light-based aesthetic and medical treatment systems with an emphasis on women's health. The company operates through four business segments which include diagnostics, breast health, medical aesthetics, GYN surgical and skeletal health. The medical aesthetics segment is the market focused segment. The medical aesthetics segment revenue is USD 278.4 million in 2018 and USD 178.3 million in 2017. The revenue has increased by 56.1% compared than previous year. The company annual revenue is USD 3,217.90 million in 2018. The company’s employees are 6,252 as of Sep 2018. The rise in revenue is because of increasing demand of cosmetic treatment. The company has its global presence in United States, Asia-Pacific, Europe, Rest of world. It operates through its subsidiaries such as Cynosure, Inc (U.S.), Gen-Probe (U.S.), Cytyc Corporation (U.S.), Third Wave Technologies, Inc (U.S.), R2 Technology, Inc (U.S.), Sentinelle Medical, Inc (Canada) and others.
